Key Takeaways
- Phase I data at ASH for BMS’s GPRC5D-targeting CAR-T showed an 18.3-month PFS, including among patients with prior CAR-T exposure.
- The data showed low rates of treatment-related weight loss, suggesting dysgeusia is less severe with arlocabtagene autoleucel than it has been with bispecific antibodies.
- It was suggested that the lower levels of dysgeusia may be due to less saturation of GPRC5D with the CAR-T compared with bispecifics, but other factors could be at play as well.
Bristol Myers Squibb is hoping that arlocabtagene autoleucel, its CAR-T cell therapy directed at GPRC5D, could provide a competitive boost over bispecific antibodies with the same target given its potentially lower incidence of
The New York-based drug maker presented Phase I data in multiple myeloma on 9 December at the American Society of Hematology annual meeting for the CAR-T, also known as arlo-cel and BMS-986393
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
